Isatuximab Brand Name– SARCLISA
What is Isatuximab
Isatuximab is a CD-38 directed cytolytic antibody indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
Because isatuximab binds to CD38 on red blood cells, it may interfere with the ability to determine a patient’s blood type and result in a false positive indirect antiglobulin test (Coombs test).
Additionally, isatuximab may interfere with the determination of complete response in some patients. Patients should have their blood typed and screened prior to starting treatment
Indications
- multiple myeloma
For the treatment of multiple myeloma
NOTE: The FDA has designated isatuximab as an orphan drug for the treatment of multiple myeloma.
for the treatment of multiple myeloma in patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor, in combination with pomalidomide and dexamethasone
Side Effects
- anemia
- anemia
- antibody formation
- bronchospasm
- chills
- cough
- diarrhea
- diarrhea
- dyspnea
- dyspnea
- hypertension
- infection
- infection
- influenza
- infusion-related reactions
- infusion-related reactions
- laryngitis
- lymphopenia
- lymphopenia
- nausea
- neutropenia
- neutropenia
- new primary malignancy
- pharyngitis
- sinusitis
- skin cancer
- thrombocytopenia
- thrombocytopenia
- tracheitis
- vomiting
- vomiting
Monitoring Parameters
- CBC with differential
- pregnancy testing
- Rh serology
- skin cancer screening exam
Contraindications
- breast-feeding
- contraception requirements
- infusion-related reactions
- laboratory test interference
- neutropenia
- new primary malignancy
- pregnancy
- pregnancy testing
- reproductive risk
- vaccination
Interactions
There are no drug interactions associated with Isatuximab products.